anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: To observe the incidence of eclampsia before and after implementing Maternal Early Warning Trigger (MEWT) tool.
STUDY DESIGN: A retrospective observational study to evaluate the effect of introduction of MEWT tool in a tertiary referral center with 10,000 annual births. Two epochs of five years duration were compared before and after implementing MEWT tool. MEWT tool has triggers for early identification of clinical deterioration and pathways for four most important maternal morbidity causes including hypertension. Hypertension pathway has emphasis on rapid control of severe acute hypertension, lab tests and magnesium sulfate prophylaxis. All pregnant women who registered and delivered at the study institute were included.
MAIN OUTCOMES MEASURES: Primary outcome was effect of MEWT tool on the incidence of eclampsia. A subset analysis was done to study the effect of MEWT tool on maternal and perinatal outcomes in women with hypertensive disease. Maternal ICU admissions, HELLP, pulmonary oedema, intracranial bleed and maternal deaths, and perinatal mean birthweight and gestational age, NICU admissions, prematurity, stillbirths, and neonatal deaths were compared.
RESULTS: The study period had 37,043 and 45,637 women in pre- and post-MEWT periods. The incidence of eclampsia reduced by 45.4 % from 1.1 to 0.6 per 1000 women (p 0.001). The most significant reduction was seen with antepartum eclampsia (0.8 to 0.3 per 1000, p = 0.02). There was significant reduction in all maternal and perinatal outcomes in women with hypertensive disorders (3,506 and 6,016 in pre- and post- MEWT periods) after introduction of MEWT tool.
CONCLUSION: Integrating the MEWT tool into the obstetric practice helps in reducing the incidence of eclampsia and improving maternal and fetal outcomes.
PROBLEM TO BE SOLVED: To achieve a link among devices differing in a group of characters.SOLUTION: In modality, character information is added to the image data of a medical image as header information, and a DICOM image file is created (step S3). Next, first character information is extracted from the header information of the DICOM image file, and based on the first character information, pixel data for overlay is created (step S4). Then, second character information described by a group of characters that cannot be handled by an image server is deleted from the header information of the DICOM image file (step S5). Pixel data for overlay is written in the header information of the DICOM image file (step S6). The DICOM image file after edition is transmitted to the image server (step S7). At an image viewer terminal, the medical image is displayed and also the first character information is overlaid and displayed (step S10).
There are many advantages of technology such as improving work productivity and efficacy; however, using technology for an extended period of time can place a substantial amount of load on the neck musculature leading to musculoskeletal disorder. The most related cause of neck pain is muscle weakness leading to forward head posture due to static abnormal posture used while using electronic devices.

The aim of the study is to compare effects of McKenzie Retraction exercises and Bruegger's exercise on neck pain, ROM, craniovertebral angle and functional performance on forward head posture among young adults. A randomized clinical trial will be conducted at Sadiq Hospital, Sargodha. Non-probability convenience sampling will be used, and 36 subjects, age 15-30 years will be randomly allocated into two groups by lottery method after meeting the inclusion criteria. Both groups will receive hot pack for 10-15 minutes, as common treatment. Group A will be treated with McKenzie Retraction Exercises and Group B will be treated with Bruegger's Exercise.5 sessions per week and total20sessions for 4 weeks. The outcome measures will be conducted through NPRS, NDI, photogrammetry and goniometry before and after 4 weeks. Data will be analyzed using SPSS software version 26.
PURPOSE:To provide a protein produced with a specific human ovarian tumor cell, having a specific mol.wt., exhibiting a multiplication-stimulating activity for vascular endothelial cells, not exhibiting the multiplication-stimulating activity for vascular smooth muscular cells, etc., and useful for cure-stimulating agent for wounds, burns, etc. CONSTITUTION:HVOCA II (FERN 2310) and HVOCA III (FERM 2311) which are human ovarian tumor cells or human ovarian tumor-established cells are cultured in a serum-free culturing medium. The supernatant of the serum-free culturing product is separated, passed through a cation exchange column, and eluted with a NaCl linear gradient. An active fraction is passed through an immobilized heparin column, and an active fraction is eluted with a NaCl linear gradient to provide the objective human-originated single strand protein having a SDS-PAGE mol.wt. of 72000-80000 dalton under a non-reducing condition, a SDS-PAGE mol.wt. of 79000-85000 under a reducing condition, having a multiplication-stimulating activity for vascular endothelial cells, not having the multiplication-stimulating activity for fibroblasts, vascular smooth muscle cells, and hepatic cells, and having a vascularizing activity.
A method and composition for hyperthermally diagnosing and monitoring treatment of cells in an animal with photoacoustic sound and nanoparticles. The heat (temperature) and photoacoustic sound wave production inside the target tissue is measured. The desired temperature is achieved using a laser and photoacoustic imaging technique. Hyperthermia treatment of tissue in a target site applies a heat source to kill cells without protein denaturation. The hyperthermia treatment may further comprise platelet-derived treatment. The method introduces an encapsulated dye that is released at a selected temperature in the target site to indicate that a threshold temperature has been reached to hyperthermally treat the tissue. In one embodiment, the composition releases the dye at a temperature of 42° C. to 56° C., and preferably about 45° C. to 49° C. The composition which can be a liposome composition encapsulating the dye can be introduced to the bloodstream of the patient to flow through the target site.
The present invention provides a drop pill for restoring pulses and a preparation method thereof, which relates to a drop pill and a preparation method thereof. The present invention solves the problem that the existing medicines for restoring pulses have the defects of first pass effect, slow effect taking and low bioavailability. The drop pill for restoring pulses is prepared from the components of the shares by weight: 1 share of concentrated thick paste or dry powder of a principal medicine and 1 to 8 shares of matrix. The concentrated thick paste or dry powder of a principal medicine comprises the components of the shares by weight: 1 share of red ginseng, 2 shares of ophiopogon root and 1 share of schisandra fruit. The preparation method comprises the following procedures: the red ginseng, the ophiopogon root and the schisandra fruit are pulverized, mixed according to the proportion by weight and subsequently dipped by ethanol; percolate is collected and concentrated or dried in a spray mode; the matrixes are proportionally added; the mixture is heated and subsequently put in a preheated pill dropping machine; the drop pill is made in a dropping mode; the drop pill are filtered, condensing agents on the surfaces of the drop pill are removed, and the drop pill for restoring pulses is obtained after the drop pill is dried. The medicine of the present invention is taken by putting the medicine under the tongue, and the medicine is absorbed by oral mucosa. The medicine takes effect in 30s to 3 min, the first pass effect of the liver and the intestine is avoided, and the bioavailability is high. The preparation technique of the present invention is simple and has high production automation degrees.
Multiple Sclerosis (MS) is an inflammatory disease of the brain leading to disability. Early treatment could allow better prognosis for the patients in the long term by reducing relapses rates and neurological palsy. However, individual prognostic biomarkers are still needed to adapt the treatment to a given patient. CSF is a strategic body fluid to explore in neurological diseases. In MS, it contains an elevated IgG index and/or oligoclonal bands reflecting the intrathecal synthesis of Igs around the brain. The levels of other inflammatory molecules such cytokines and metalloproteases are also known to be elevated in MS (GM-CSF, IL-6, IL-10, MMP-2, MMP9, TIMP-1, TNF-α, RANTES, MCP-1 and MIP-1). These molecules can now be easily measured by protein arrays.The aim of this study is to measure the level of 40 cytokines and 10 MMPs by means of protein arrays in the CSF from clinically definite MS (CDMS) patients, control patients and patients with a clinically isolated syndrome (CIS). The best MS markers will be determined using multiple ROC curves. Markers of rapid conversion to CDMS after a CIS will also be looked for.The best MS candidate biomarkers will be analyzed by ELISA in a new cohort of patients being recruited.
Mosaic loss of chromosome Y (mLOY) is the most common somatic alteration as men aging and may reflect genome instability. PM exposure is a major health concern worldwide, but its effects with genetic factors on mLOY has never been investigated. Here we explored the associations of PM2.5 and PM10 exposure with mLOY of 10,158 males measured via signal intensity of 2186 probes in male-specific chromosome-Y region from Illumina array data. The interactive and joint effects of PM2.5 and PM10 with genetic factors and smoking on mLOY were further evaluated. Compared with the lowest tertiles of PM2.5 levels in each exposure window, the highest tertiles in the same day, 7-, 14-, 21-, and 28-day showed a 0.005, 0.006, 0.007, 0.007, and 0.006 decrease in mLRR-Y, respectively (all P < 0.05), with adjustment for age, BMI, smoking pack-years, alcohol drinking status, physical activity, education levels, season of blood draw, and experimental batch. Such adverse effects were also observed in PM10-mLOY associations. Moreover, the unweighted and weighted PRS presented significant negative associations with mLRR-Y (both P < 0.001). Participants with high PRS and high PM2.5 or PM10 exposure in the 28-day separately showed a 0.018 or 0.019 lower mLRR-Y level [β (95 %CI) = -0.018 (-0.023, -0.012) and - 0.019 (-0.025, -0.014), respectively, both P < 0.001], when compared to those with low PRS and low PM2.5 or PM10 exposure. We also observed joint effects of PM with smoking on exacerbated mLOY. This large study is the first to elucidate the impacts of PM2.5 exposure on mLOY, and provides key evidence regarding the interactive and joint effects of PM with genetic factors on mLOY, which may promote understanding of mLOY development, further modifying and increasing healthy aging in males.
The invention relates to a method to extract edelweiss ingredients, use thereof and a composition. It is well known that there are about 30 sub-species among the species of edelweiss. At least in Europe, these species are protected by law and are therefore cultivated. The ingredients extracted therefrom are not only extremely expensive, but they are also overwhelmingly unstable. In this regard, the invention provides assistance via a method comprising the following steps: a. Harvesting the Asian species of edelweiss Leontopodium ochroleuceum and/or Leontopodium leontopoides and/or Leontopodium himalayanum with the leaves, blossoms, stalks, and/or roots, b. Subsequently drying and freeze-drying and processing into powder, c. Extracting the resulting powder with an alcohol solution and agitation thereof for a plurality of hours, in particular 24 hours, d. Separating the solids and optionally concentrating the extracted alcohol solution, e. Stabilizing the solution by way of a preservative containing paraben and optionally completely removing the alcohol. The composition according to the invention is especially suited for dental care.
This study entailed a comprehensive GC‒MS analysis conducted on 121 patient samples to generate a clinical breathomics dataset. Breath molecules, indicative of diverse conditions such as psychological and pathological states and the microbiome, were of particular interest due to their non-invasive nature. The highlighted noninvasive approach for detecting these breath molecules significantly enhances diagnostic and monitoring capacities. This dataset cataloged volatile organic compounds (VOCs) from the breath of individuals with asthma, bronchiectasis, and chronic obstructive pulmonary disease. Uniform and consistent sample collection protocols were strictly adhered to during the accumulation of this extensive dataset, ensuring its reliability. It encapsulates extensive human clinical breath molecule data pertinent to three specific diseases. This consequential clinical breathomics dataset is a crucial resource for researchers and clinicians in identifying and exploring important compounds within the patient's breath, thereby augmenting future diagnostic and therapeutic initiatives.
BACKGROUND: Awareness-raising and education have been identified as strategies to counter the taboo surrounding death and dying. As the favoured venue for youth education, schools have an essential role to play in informing future decision-makers. However, school workers are not comfortable addressing the subjects of death and dying, which, unlike other social issues, have no guidelines to influence awareness of these subjects in youth.
OBJECTIVES: To systematically explore the knowledge and practices on raising awareness about death and dying in schools, the viewpoints of the people involved (young people, school workers; parents), and the factors that either promote or hinder awareness practices.
METHOD: The scoping review method of Levac and Colquhoun (Implement Sci 5(1):69, 2010) will be used. Using a combination of keywords and descriptors, a body of literature will be identified through 15 databases and through grey literature searches, manual searches, consultation of key collaborators, and the list of relevant literature. Publications since 2009 will be selected if they relate directly to awareness-raising about death and dying in schools. Writings will be selected and extracted by two independent people, and conflicts resolved by consensus. The extracted data will be synthesized using a thematic analysis method. Experts from a variety of disciplines (health sciences, humanities, social sciences, and education) will be consulted to enhance the interpretation of the preliminary results. Results will be presented in narrative form and will include tables and diagrams.
CONCLUSION: The results of this scoping review will contribute to the development of educational practices adapted to young people and to the identification of future avenues of research on awareness of death and dying.
A silicon-titanium mixed oxide powder contains aggregates of primary particles selected from amorphous silicon dioxide particles, crystalline titanium dioxide particles, and silicon-titanium mixed oxide particles each having an amorphous silicon dioxide fraction and a crystalline titanium dioxide fraction. The silicon-titanium mixed oxide particles predominate in the powder. The powder exhibits a BET surface area of from 20 to 200 m2/g, and a titanium dioxide content in a range of from greater than 10 wt. % to less than 70 wt. %. An X-ray diffractogram of the powder exhibits the diffraction patterns of rutile and anatase, with a rutile/anatase ratio of from 2:98 to 98:2. The powder can be produced by vaporizing a silicon halide and a titanium halide at temperatures of less than 180 DEG C., performing combustion with hydrogen and air in a reaction chamber that is closed off from the earth's atmosphere, separating the solids from gaseous substances, and subsequently removing halide-containing substances from the solids to the greatest possible extent by treatment with steam at temperatures of from 250 to 700 DEG C. The powder can be used in toners.
Nt-proBNP levels as well as their response to pharmacological treatment are predictive of prognosis in patients with heart failure. The purpose of the present project is to investigate, in patients hospitalized with acute heart failure, whether a discharge decision guided by Nt-proBNP response shortens hospital stay and improves prognosis The included patients will be randomly assigned to one of these two strategies: hospital discharge according to clinical conventional criteria or discharge guided by Nt-proBNP. All patients will be treated following clinical guidelines. In the guided Nt-proBNP strategy, patients will be discharged the third day if NT-proBNP levels drops \>30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. In the conventional strategy, patients will be discharged at criterion of the attending cardiologist according to clinical assessment without Nt-proBNP. The main outcome will be the number of days of hospitalization at the index episode, and the secondary outcome will be death or readmission by heart failure at one and 6 months. Our hypothesis is that the Nt-proBNP guided discharge will allow to precisely evaluate the response to treatment and to determine the best time for hospital discharge. This will reduce hospital stay and death or readmission rate after discharge.
BACKGROUND: Small-bore wire-guided thoracostomy tubes (SBWGTT) are commonly used in cats to manage pleural disease and generally have a low complication rate. Our study aimed to explore the correlation between recumbency of cats, placement method, and the occurrence of insertional complications to identify risk factors during SBWGTT placement. In this experimental cadaveric study, SBWGTT placement using a modified Seldinger technique was conducted in 24 feline cadavers. Cats, euthanized for reasons unrelated to the study, were randomly assigned to pleural effusion (EFF; n = 12) and pneumothorax (PNEU; n = 12) groups. Each cadaver was intubated and ventilated with a peak inspiratory pressure (PIP) of 10 mmHg, and sterile saline or air was instilled into the thorax over a 5 mm thoracoscopic trocar in the fourth intercostal space (ICS). Instillation was stopped when the lateral thoracic wall to lung distance (TWLD) reached 10 to 12 mm, measured with ultrasound in the favorable position. Sternal recumbency was the favorable position for the EFF group, and lateral recumbency for the PNEU group. Following the placement of the first SBWGTT in each group, the cadavers were positioned unfavorably (lateral recumbency for EFF group, sternal recumbency for PNEU group), and a second drain was introduced contralaterally. A bilateral 8th ICS thoracotomy was then performed to visually assess intrathoracic structures and drain integrity. A binary logistic regression mixed model was conducted to determine interaction between the induced condition and body position.
RESULTS: A total of 48 SBWGTTs were placed, with complications observed in 33.3% (8/24) of cases. Five of these were major complications consisting of lung lacerations. Complications were more common in the unfavorable position, accounting for 75% of cases, although this result was not statistically significant. The odds of complication rates were > 70% in the unfavorable position and decreased with an increase in TWLD (< 30%).
CONCLUSION: Complications associated with SBWGTT placement are influenced by recumbency, although the data did not reach statistical significance. Placing cats in lateral recumbency for pneumothorax treatment and sternal recumbency for pleural effusion treatment may reduce insertional complications.
The present invention relates to a pill for treating collateral and gynecological diseases, and belongs to the field of traditional Chinese medicines. The pill is prepared from raw materials: 10 to 50 portions of cantharis, 10 to 50 portions of dragon's blood, 10 to 50 portions of croton, 10 to 50 portions of catechu, 10 to 50 portions of myrrh and 10 to 50 portions of frankincense. The crotons are peeled, the oil is removed, and the residues are taken. The heads, the feet and the wings of cantharides are removed. The six kinds of crude drugs are ground into fine powder by the weight proportion, and honey is added to be fine powder to be rolled into pills. The pills are put in a sterile gauze bag with a pull rope to be spare. The pill has the advantage that the pill for treating collateral and gynecological diseases covers the whole body, the channel system of the whole body is thoroughly improved from head to foot, and wind cold, rheumatism, neuralgia and gynecology inflammation caused by various reasons can be effectively treated; the cure rate for treating patients with uterine cold infertility can achieve 100%; the effective rate for treating patients with wind cold damp impediment periphery arthralgia can achieve 99.9%; the treatment course is short; the cost is low.
A product for providing a customized color shade sunscreen product to match a skin tone of a subject is provided, which comprises a color dose formulation, an instruction and optionally a sunscreen. The color dose formulation has high concentration of pigments and is suitable for being mixed with a sunscreen to prepare a customized color shade sunscreen product. Also provided is a method of preparing a customized color shade sunscreen product to match a skin tone. Such method comprises mixing a selected color dose formulation with a sunscreen. The formulations may be selected from six color shade compositions that offer color shades suitable for all skin tones. The customized color shade sunscreen product may provide a sensorial benefit such as dry touch, good spreadability, no white residues, oil control and protection against UV rays, infrared rays and visible light.
Participants will complete the Aliviado DSD Caregiving Mastery Program. This involves a caregiver education/training period from Week 0 to Week 2, and an implementation period from Week 3 to Week 6.
The HIV epidemic is a major global health challenge, causing tremendous human suffering and economic loss throughout the world. The need for a safe, effective, and affordable HIV preventive vaccine is critical. This study will determine the safety and immunogenicity of an experimental HIV vaccine, HIV-1 gag DNA, given with or without an IL-12 adjuvant and boosted HIV-1 gag DNA with or without IL-12 DNA adjuvant.

This study will comprise two parts (Parts A and B). Part A will last 9 months and Part B, 15 months. Part A will consist of 48 participants enrolled in 4 groups. Group 1 participants will be randomly assigned to receive the gag DNA vaccine or placebo. Participants in Groups 2, 3, and 4 will be randomly assigned to receive the gag DNA vaccine and either 100 mcg, 500 mcg, or 1,500 mcg IL-12 DNA or placebo. Vaccinations for Groups 1 through 4 will be given intramuscularly and will occur at study entry and at Months 1 and 3.

Part B will consist of 96 participants, enrolled in 3 groups. Participants in Part B will receive their first vaccination 2 weeks after Part A participants receive their second vaccination. Group 5 participants will receive either the HIV-1 gag DNA vaccine or placebo. Group 6 participants will receive either the HIV-1 gag DNA vaccine plus IL-12 DNA or placebo. Vaccinations for Groups 5 and 6 will occur at study entry and at Months 1, 3, 6, and 9. Group 7 participants will receive either the gag DNA vaccine plus IL-12 DNA or placebo at study entry and at Months 1 and 3. Throughout the study, blood and urine collections will occur, physical exams will be conducted, HIV testing and counseling will be offered, and interviews and questionnaires will be completed.